Welcome to our dedicated page for Cresco Labs news (Ticker: CRLBF), a resource for investors and traders seeking the latest updates and insights on Cresco Labs stock.
Cresco Labs Inc. (CRLBF) generates a steady flow of news related to its cannabis cultivation, production, branded products and Sunnyside retail dispensaries. As a company that emphasizes a CPG approach to national cannabis brands and a customer-focused retail experience, its announcements often highlight new store openings, market entries and updates on financial performance.
Readers of this news feed can expect coverage of dispensary openings and expansions, such as new Sunnyside locations in regulated medical marijuana and adult-use markets. These stories typically describe how each store fits into Cresco Labs’ broader national footprint and its efforts to provide an educational, approachable retail environment for patients and consumers.
The company also issues financial and operating results updates, including quarterly earnings releases that outline revenue, gross profit, net income or loss and non-GAAP metrics like Adjusted EBITDA and Adjusted gross profit. These releases are often paired with information about conference calls and webcasts for investors, as well as references to related filings on SEDAR+ and EDGAR.
Another key category of Cresco Labs news involves capital structure and financing. The company has announced commitments and closings for senior secured term loan refinancings, describing how these transactions affect its debt profile, maturity schedule and financial flexibility.
Policy and regulatory developments also appear in the news flow. Cresco Labs has commented on significant changes in U.S. cannabis regulation, including federal rescheduling actions, and has framed these events in the context of its mission to normalize and professionalize the cannabis industry. For investors and observers, following CRLBF news provides insight into how the company is expanding its brand portfolio, managing its balance sheet and responding to evolving cannabis laws.
Cresco Labs (OTCQX: CRLBF) entered an equity distribution agreement with Haywood Securities to establish an at-the-market (ATM) program to sell up to ~US$100 million (C$140 million) of subordinate voting shares.
Proceeds are intended for general corporate purposes, including potential acquisitions; no shares have been sold to date. The program is offered under a prospectus supplement dated January 29, 2026, and sales will occur on Canadian marketplaces in compliance with applicable securities laws.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Tamarac at 6001 N University Drive in Tamarac, Florida, marking its 31st dispensary in Florida and 72nd location nationwide.
The store offers products from Cresco Labs' brand portfolio including Cresco, FloraCal, Supply, Good News, Remedi and Sunnyside, plus accessories; orders can be placed in store or online at www.sunnyside.shop. Store hours: Monday–Friday 9:00 a.m.–8:00 p.m.; Sunday 9:00 a.m.–6:00 p.m.
Cresco Labs (OTCQX: CRLBF) issued a CEO statement after President Trump rescheduled cannabis from Schedule I to Schedule III under the Controlled Substances Act on December 18, 2025. The company called the move a historic shift that enables expanded medical research, eases the industry's federal tax burden, and advances banking reform and U.S. capital market access. The statement cited public support figures and noted implications for the estimated 450,000 workers in the regulated cannabis industry.
Cresco Labs (OTCQX: CRLBF) announced on November 12, 2025 the commercial launch of Cresco-branded flower in Germany, marking the company's first entry into the European Union.
The company is piloting three signature flower products, partnered with Blossom, an EU GMP-certified manufacturer in Portugal, and will distribute products via prescription through licensed pharmacies across Germany. The launch is presented as a market-entry pilot to gather insights to guide future international expansion.
Cresco Labs (OTCQX: CRLBF) reported Q3 2025 revenue of $165 million and gross profit of $79 million, with an Adjusted gross margin of 48.8%. The company posted Adjusted EBITDA of $40 million (24.1% margin) and operating cash flow of $6 million, while reporting a net loss of $22 million that included a $16 million loss on debt extinguishment and $2 million impairment charges. On August 13, 2025, Cresco closed a refinancing: a new $325 million senior secured term loan at 12.5% interest maturing August 13, 2030, used to repay a prior $360 million facility. Cash and equivalents totaled $79 million at quarter end.
Cresco Labs (OTCQX: CRLBF) will report third quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, November 5, 2025 before the market opens.
The company will host an earnings conference call and webcast on the same day at 8:30 am ET to discuss results and provide investor highlights. Dial-in numbers, an access code, registration links, and a webcast link are provided for live participation. The webcast archive will be available for one year on the Cresco Labs investor relations website.
Cresco Labs (OTCQX: CRLBF) held its annual general and special meeting of shareholders on September 16, 2025, where several key corporate governance matters were approved with overwhelming shareholder support of at least 96% for each item.
Shareholders approved fixing the board size at seven directors and elected all nominated directors including Charles Bachtell, Gerald F. Corcoran, Robert M. Sampson, Thomas J. Manning, Marc Lustig, Michele Roberts, and Randy D. Podolsky. Baker Tilly US, LLP was appointed as the company's auditor.
Additionally, shareholders approved an Award Exchange Program allowing certain employees to exchange underwater options for full value awards with new three-year vesting terms, aimed at better aligning employee compensation with shareholder interests.
Cresco Labs (OTCQX:CRLBF) has announced the opening of a new Sunnyside dispensary in Proctorville, Ohio, marking its sixth location in Ohio and 71st nationwide. The strategic location at 200 State Street is significant as it's the only dispensary within a 45-mile radius.
The expansion aligns with Cresco's market leadership, as the company currently holds the number one position in retail market share and ranks third in branded product share in Ohio. The company plans to open two more dispensaries in Ohio in the coming months, further strengthening its presence in the state.
Cresco Labs (OTCQX:CRLBF) has successfully closed a $325 million senior secured term loan refinancing, replacing its previous $360 million facility. The new loan features a 12.5% annual interest rate and extends maturity to August 13, 2030.
The refinancing strengthens the company's balance sheet by reducing total debt and provides enhanced flexibility to prepay up to $125 million at a reduced premium. The facility contains no equity or convertible features and includes standard financial and operational covenants.
Cresco Labs (OTCQX:CRLBF) reported solid Q2 2025 financial results with revenue of $164 million and Adjusted EBITDA of $41 million, maintaining a 25% EBITDA margin. The company generated $9 million in operating cash flow and achieved a gross margin of 50.6%.
A significant milestone includes securing a commitment letter for a new $325 million term loan to refinance existing debt, strengthening the company's balance sheet and financial flexibility. The quarter saw a net loss of $14 million, which includes $9 million in non-cash impairment charges related to California assets.
The company maintained its #1 market share position in multiple billion-dollar markets while positioning itself for strategic M&A opportunities in the consolidating cannabis industry.
FAQ
What is the current stock price of Cresco Labs (CRLBF)?
What is the market cap of Cresco Labs (CRLBF)?
